Oncostem Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -43.66%
(FY 2023)
- Profit -2016.27%
(FY 2023)
- Ebitda -1908.01%
(FY 2023)
- Net Worth -40.95%
(FY 2023)
- Total Assets 7.11%
(FY 2023)
About Oncostem Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Thallam Satyanarayana and Manjiri Bakre serve as directors at the Company.
- CIN/LLPIN
U85110KA2011PTC057624
- Company No.
057624
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2011
- Date of AGM
20 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Oncostem Diagnostics Private Limited offer?
Oncostem Diagnostics Private Limited offers a wide range of products and services, including Medical Treatment Services, Breast Cancer Treatment.
Who are the key members and board of directors at Oncostem Diagnostics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thallam Satyanarayana  | Director | 06-Apr-2022 | Current |
| Manjiri Bakre | Director | 17-Jun-2011 | Current |
Financial Performance and Corporate Structure Insights of Oncostem Diagnostics.
Oncostem Diagnostics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 43.66% decrease. The company also saw a substantial fall in profitability, with a 2016.27% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncostem Diagnostics?
In 2023, Oncostem Diagnostics had a promoter holding of 97.96% and a public holding of 2.04%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oncostem Diagnostics?
Oncostem Diagnostics has a workforce of 17 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncostem Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncostem Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
